NASDAQ: ATOS
Atossa Therapeutics Inc Stock Ownership - Who owns Atossa Therapeutics?

Insider buying vs selling

Have Atossa Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Steven C. QuayPresident CEO2025-05-2111,239$0.88
$9.89kBuy
H. Lawrence RemmelDirector2025-03-2610,000$0.70
$7.00kBuy

1 of 1

ATOS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ATOS insiders and whales buy or sell their stock.

ATOS Shareholders

What type of owners hold Atossa Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc7.45%9,625,365$8.00MInstitution
Shuchih Chen7.04%9,095,173$7.56MInsider
Vanguard Group Inc5.10%6,585,912$5.47MInstitution
Steven C. Quay3.76%4,863,010$4.04MInsider
Geode Capital Management LLC2.20%2,845,792$2.36MInstitution
Renaissance Technologies LLC1.44%1,855,101$1.54MInstitution
State Street Corp1.34%1,727,090$1.44MInstitution
Northern Trust Corp0.75%973,998$809.39kInstitution
Squarepoint Ops LLC0.37%478,999$398.05kInstitution
Ubs Group Ag0.35%455,386$378.43kInstitution

1 of 3

ATOS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ATOS21.95%11.04%Net BuyingNet Buying
HURA8.37%43.24%
EXOZ0.56%99.44%Net Buying
ANIX17.08%82.92%Net BuyingNet Buying
NTHI0.31%91.78%Net BuyingNet Buying

Atossa Therapeutics Stock Ownership FAQ

Who owns Atossa Therapeutics?

Atossa Therapeutics (NASDAQ: ATOS) is owned by 21.95% institutional shareholders, 11.04% Atossa Therapeutics insiders, and 67.01% retail investors. Shuchih Chen is the largest individual Atossa Therapeutics shareholder, owning 9.10M shares representing 7.04% of the company. Shuchih Chen's Atossa Therapeutics shares are currently valued at $7.56M.

If you're new to stock investing, here's how to buy Atossa Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.